Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.
Del Campo J, Pizzorno A, Djebali S, Bouley J, Haller M, Pérez-Vargas J, Lina B, Boivin G, Hamelin ME, Nicolas F, Le Vert A, Leverrier Y, Rosa-Calatrava M, Marvel J, Hill F. Del Campo J, et al. NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019. NPJ Vaccines. 2019. PMID: 30701093 Free PMC article.
OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza.
Del Campo J, Bouley J, Chevandier M, Rousset C, Haller M, Indalecio A, Guyon-Gellin D, Le Vert A, Hill F, Djebali S, Leverrier Y, Marvel J, Combadière B, Nicolas F. Del Campo J, et al. Front Immunol. 2021 Jun 10;12:678483. doi: 10.3389/fimmu.2021.678483. eCollection 2021. Front Immunol. 2021. PMID: 34177921 Free PMC article.
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Leroux-Roels I, Waerlop G, Tourneur J, De Boever F, Maes C, Bruhwyler J, Guyon-Gellin D, Moris P, Del Campo J, Willems P, Leroux-Roels G, Le Vert A, Nicolas F. Leroux-Roels I, et al. Among authors: del campo j. Front Immunol. 2022 Apr 7;13:852904. doi: 10.3389/fimmu.2022.852904. eCollection 2022. Front Immunol. 2022. PMID: 35464450 Free PMC article. Clinical Trial.
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Minhinnick A, Satti I, Harris S, Wilkie M, Sheehan S, Stockdale L, Manjaly Thomas ZR, Lopez-Ramon R, Poulton I, Lawrie A, Vermaak S, Le Vert A, Del Campo J, Hill F, Moss P, McShane H. Minhinnick A, et al. Among authors: del campo j. Vaccine. 2016 Mar 8;34(11):1412-21. doi: 10.1016/j.vaccine.2016.01.062. Epub 2016 Feb 5. Vaccine. 2016. PMID: 26854906 Free PMC article. Clinical Trial.
Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine.
Pérez O, Bracho G, Lastre M, Zayas C, González D, Gil D, del Campo J, Acevedo R, Taboada C, Rodríguez T, Fajardo ME, Sierra G, Campa C, Mora N, Barberá R, Solís RL. Pérez O, et al. Among authors: del campo j. Vaccine. 2006 Apr 12;24 Suppl 2:S2-52-3. doi: 10.1016/j.vaccine.2005.01.127. Vaccine. 2006. PMID: 16823925
New method for obtaining conjugated vaccines.
Cabrera O, Cuello M, Soto CR, Martínez ME, del Campo JM, Pérez Oa, Infante JF, Sierra G. Cabrera O, et al. Vaccine. 2006 Apr 12;24 Suppl 2:S2-76-8. doi: 10.1016/j.vaccine.2005.01.131. Vaccine. 2006. PMID: 16823936
348 results